AP2012006242A0 - Anticoagulant antidotes. - Google Patents

Anticoagulant antidotes.

Info

Publication number
AP2012006242A0
AP2012006242A0 AP2012006242A AP2012006242A AP2012006242A0 AP 2012006242 A0 AP2012006242 A0 AP 2012006242A0 AP 2012006242 A AP2012006242 A AP 2012006242A AP 2012006242 A AP2012006242 A AP 2012006242A AP 2012006242 A0 AP2012006242 A0 AP 2012006242A0
Authority
AP
ARIPO
Prior art keywords
antidotes
anticoagulant
anticoagulant antidotes
Prior art date
Application number
AP2012006242A
Other languages
English (en)
Inventor
Joanne Van Ryn
Nobert Hauel
Tobias Litzenburger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42061991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2012006242(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2012006242A0 publication Critical patent/AP2012006242A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626Diabody or triabody
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AP2012006242A 2010-01-20 2011-01-20 Anticoagulant antidotes. AP2012006242A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10151239 2010-01-20
US38391410P 2010-09-17 2010-09-17
PCT/EP2011/050749 WO2011089183A2 (en) 2010-01-20 2011-01-20 Anticoagulant antidotes

Publications (1)

Publication Number Publication Date
AP2012006242A0 true AP2012006242A0 (en) 2012-04-30

Family

ID=42061991

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006242A AP2012006242A0 (en) 2010-01-20 2011-01-20 Anticoagulant antidotes.

Country Status (43)

Country Link
US (3) US8486398B2 (es)
EP (2) EP3195876A1 (es)
JP (2) JP5575923B2 (es)
KR (1) KR101781787B1 (es)
CN (1) CN102711813B (es)
AP (1) AP2012006242A0 (es)
AR (1) AR079944A1 (es)
AU (1) AU2011208719C1 (es)
BR (1) BR112012018021B1 (es)
CA (1) CA2787566A1 (es)
CO (1) CO6571889A2 (es)
CY (2) CY1118875T1 (es)
DK (1) DK2525812T3 (es)
EA (1) EA028371B1 (es)
EC (1) ECSP12012105A (es)
ES (1) ES2614992T3 (es)
FR (1) FR17C1026I2 (es)
GE (1) GEP20156341B (es)
HR (1) HRP20170613T1 (es)
HU (2) HUE032263T2 (es)
IL (1) IL219427B (es)
LT (2) LT2525812T (es)
LU (1) LUC00028I2 (es)
MA (1) MA33936B1 (es)
ME (1) ME02602B (es)
MX (1) MX2012008360A (es)
MY (1) MY162323A (es)
NL (1) NL300882I2 (es)
NO (2) NO2017034I1 (es)
NZ (1) NZ599508A (es)
PE (1) PE20121516A1 (es)
PH (1) PH12012501493A1 (es)
PL (1) PL2525812T3 (es)
PT (1) PT2525812T (es)
RS (1) RS55683B1 (es)
SG (1) SG182552A1 (es)
SI (1) SI2525812T1 (es)
TN (1) TN2012000366A1 (es)
TW (1) TWI513466B (es)
UA (1) UA110470C2 (es)
UY (1) UY33196A (es)
WO (1) WO2011089183A2 (es)
ZA (1) ZA201202876B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
CN103619883A (zh) * 2011-01-19 2014-03-05 拜耳知识产权有限责任公司 凝血因子抑制剂的结合蛋白
PE20140964A1 (es) * 2011-03-30 2014-08-17 Boehringer Ingelheim Int Antidotos anticoagulantes
US9522892B2 (en) 2011-11-29 2016-12-20 Perosphere Inc. Anticoagulant reversal agents
SG11201506886TA (en) 2013-03-14 2015-09-29 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
EP3060583A1 (en) 2013-10-25 2016-08-31 Boehringer Ingelheim International GmbH Anticoagulant antidotes
TW201623331A (zh) * 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
CN105223348A (zh) * 2014-05-26 2016-01-06 北京九强生物技术股份有限公司 人抗凝血酶iii的胶乳增强免疫比浊法检测试剂盒
EP2980218A1 (en) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
US10501773B2 (en) * 2014-07-31 2019-12-10 Haemonetics Corporation Detection and classification of an anticoagulant using a clotting assay
WO2016044645A1 (en) * 2014-09-17 2016-03-24 Elmaleh David R Anticoagulant derivatives for cardiovascular imaging
EP3251672B1 (en) 2014-12-31 2023-02-01 Shenzhen Pharmacin Co., Ltd. Pharmaceutical composition comprising dabigatran etexilate and preparation method therefor
CN105816437B (zh) 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
WO2019124468A1 (ja) * 2017-12-24 2019-06-27 ノイルイミューン・バイオテック株式会社 ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞
US10752691B2 (en) 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
CA3099974A1 (en) * 2018-05-11 2019-11-14 Halcyon Therapeutics, Inc. Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof
CA3117599A1 (en) 2018-10-29 2020-05-07 Huahai Us Inc. Novel dipeptide compounds and uses thereof
WO2020180489A1 (en) 2019-03-06 2020-09-10 University Of Rochester Anticoagulant compositions and uses thereof
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
TW202321311A (zh) * 2021-08-02 2023-06-01 日商諾伊爾免疫生物科技股份有限公司 與scFv等之連接子結合的抗體
US11446286B1 (en) * 2022-02-28 2022-09-20 King Faisal University Treatment of fungal infections using dabigatran etexilate
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69309472T2 (de) * 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
DE19729544A1 (de) * 1997-07-10 1999-01-14 Basf Ag Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20070031438A1 (en) * 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
TW201124143A (en) 2009-08-24 2011-07-16 Boehringer Ingelheim Int Emergency interventions of active charcoal with dabigatran etexilate overdosing
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Also Published As

Publication number Publication date
KR101781787B1 (ko) 2017-09-26
LUC00028I2 (es) 2017-09-25
ES2614992T3 (es) 2017-06-02
WO2011089183A2 (en) 2011-07-28
EP2525812A2 (en) 2012-11-28
HUS1700030I1 (hu) 2017-08-28
FR17C1026I1 (fr) 2017-09-08
HK1173957A1 (en) 2013-05-31
PL2525812T3 (pl) 2017-07-31
JP2013517317A (ja) 2013-05-16
HUE032263T2 (en) 2017-09-28
LTPA2017021I1 (lt) 2017-07-25
US20120027780A1 (en) 2012-02-02
BR112012018021A2 (pt) 2017-06-20
WO2011089183A3 (en) 2011-11-17
FR17C1026I2 (fr) 2018-07-20
UY33196A (es) 2011-08-31
EP2525812B1 (en) 2017-01-18
SG182552A1 (en) 2012-08-30
KR20120128126A (ko) 2012-11-26
CN102711813B (zh) 2015-03-04
UA110470C2 (ru) 2016-01-12
JP5575923B2 (ja) 2014-08-20
LTC2525812I2 (lt) 2019-05-10
NZ599508A (en) 2014-05-30
CA2787566A1 (en) 2011-07-28
US9034822B2 (en) 2015-05-19
AR079944A1 (es) 2012-02-29
CY1118875T1 (el) 2018-01-10
PH12012501493A1 (en) 2012-10-22
CY2017025I1 (el) 2017-11-14
TN2012000366A1 (en) 2014-01-30
BR112012018021B1 (pt) 2020-12-08
PT2525812T (pt) 2017-04-26
DK2525812T3 (en) 2017-02-27
NO2017034I1 (no) 2017-07-11
CN102711813A (zh) 2012-10-03
ECSP12012105A (es) 2012-10-30
MA33936B1 (fr) 2013-01-02
SI2525812T1 (sl) 2017-05-31
NL300882I2 (nl) 2017-07-20
LUC00028I1 (es) 2017-07-14
US20130289248A1 (en) 2013-10-31
IL219427A0 (en) 2012-06-28
RS55683B1 (sr) 2017-07-31
GEP20156341B (en) 2015-08-10
CY2017025I2 (el) 2017-11-14
US8486398B2 (en) 2013-07-16
CO6571889A2 (es) 2012-11-30
HRP20170613T1 (hr) 2017-06-30
MX2012008360A (es) 2012-08-08
ME02602B (me) 2017-06-20
JP2014210794A (ja) 2014-11-13
TW201136606A (en) 2011-11-01
PE20121516A1 (es) 2012-11-24
MY162323A (en) 2017-05-31
EA028371B1 (ru) 2017-11-30
EA201201016A1 (ru) 2013-02-28
IL219427B (en) 2018-05-31
ZA201202876B (en) 2012-12-27
US20150210778A1 (en) 2015-07-30
AU2011208719C1 (en) 2017-07-13
EP3195876A1 (en) 2017-07-26
NO2022036I1 (no) 2022-08-12
LT2525812T (lt) 2017-02-27
TWI513466B (zh) 2015-12-21
AU2011208719A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
AP2012006242A0 (en) Anticoagulant antidotes.
GB201106792D0 (en) .
GB201206830D0 (en) .
GB201104434D0 (en) .
GB201115796D0 (en) .
GB201106766D0 (en) .
GB201118961D0 (en) .
GB201118592D0 (en) .
AP2013007046A0 (en) Anticoagulant antidotes
GB201122114D0 (en) .
GB201104448D0 (en) .
GB201203063D0 (en) .
GB201104429D0 (en) .
GB201102141D0 (en) .
GB201115799D0 (en) .
GB201114750D0 (en) .
GB201202620D0 (en) .
GB201122259D0 (en) .
GB201119853D0 (en) .
GB201104430D0 (en) .
GB201117584D0 (en) .
AU2011100252A4 (en) Catch the Coasters
GB201011244D0 (en) .
GB201007038D0 (en) .
GB201000368D0 (en) .